{"id":244,"date":"2010-03-31T10:10:10","date_gmt":"2010-03-31T01:10:10","guid":{"rendered":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/2010\/03\/31\/200315\/"},"modified":"2017-09-06T11:22:49","modified_gmt":"2017-09-06T02:22:49","slug":"200315","status":"publish","type":"post","link":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/achievement\/20100331244\/","title":{"rendered":"2003\u5e74\u307e\u3067\u306e\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"

A. \u8ad6\u6587<\/h3>\n

\u3010\u8457\u66f8\u3011<\/h4>\n
    \n
  1. Mueller NE, Tachibana N, Stuver SO, Okayama A, Ishizaki J, Shishime E, Murai K, Shigemasa S, Tsuda K. Epidemiologic Perspectives of HTLV-I. In: Human Retrovirology HTLV, ed. Blattner AW, pp.281-293(1990).Raven Press Ltd, New York.<\/li>\n
  2. Okayama A, Ishizaki J, Tachibana N, Tsuda K, Essex M, Mueller NE. The particle agglutination (PA) assay and its use in detecting lower titer HTLV-I antibodies, HTLV-I. In: Human Retrovirology HTLV, ed. Blattner AW, pp.401- 407(1990). Raven Press Ltd, New York.<\/li>\n
  3. \u9ce5\u5c45\u672c\u7f8e, \u6cb3\u91ce\u8302, \u5ca1\u5c71\u662d\u5f66. \u611f\u67d3\u75c7\u304a\u3088\u3073\u5bc4\u751f\u866b\u75be\u60a3. \u533b\u7642\u7981\u5fcc\u30de\u30cb\u30e5\u30a2\u30eb, \u5bcc\u91ce\u5eb7\u65e5\u5df1, 182-186 (1999). \u533b\u6b6f\u85ac\u51fa\u7248\u682a\u5f0f\u4f1a\u793e,\u3000\u6771\u4eac.<\/li>\n
  4. \u5ca1\u5c71\u662d\u5f66. \u611f\u67d3\u75c7. \u6839\u62e0\u304c\u308f\u304b\u308b\u30ca\uff0d\u30b9\u306e\u305f\u3081\u306e\u533b\u7642\u7981\u5fcc\u30bb\u30eb\u30d5\u30c1\u30a7\u30c3\u30af, \u5bcc\u91ce\u5eb7\u65e5\u5df1, \u6afb\u4e95\u7f8e\u9234, 137-139(2001). \u682a\u5f0f\u4f1a\u793e\u5357\u6c5f\u5802, \u6771\u4eac.<\/li>\n
  5. \u5ca1\u5c71\u662d\u5f66. \u30ea\u30b1\u30c3\u30c1\u30a2\u611f\u67d3\u75c7.\u3000\u611f\u67d3\u75c7\u8a3a\u7642\u30cf\u30f3\u30c9\u30d6\u30c3\u30af, \u90a3\u9808\u52dd, 280-287(2001). \u682a\u5f0f\u4f1a\u793e\u3000\u4e2d\u5916\u533b\u5b66\u793e,\u6771\u4eac.<\/li>\n
  6. \u5b87\u91ce\u6b66\u53f8, \u5ca1\u5c71\u662d\u5f66. \u767a\u71b1.\u3000\u9ebb\u9154\u79d1\u8a3a\u7642\u30d7\u30e9\u30af\u30c6\u30a3\u30b9\uff14\u3000\u764c\u6027\u75bc\u75db\u7ba1\u7406, \u5f13\u524a\u5b5f\u6587, 242-243(2001). \u682a\u5f0f\u4f1a\u793e \u6587\u5149\u5802, \u6771\u4eac.<\/li>\n
  7. \u5ca1\u5c71\u662d\u5f66, \u6a58\u5ba3\u7965. HTLV-I\u30ad\u30e3\u30ea\u30a2\u306e\u9577\u671f\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7. \u30d2\u30c8\u30ec\u30c8\u30ed\u30a6\u30a4\u30eb\u30b9\u7814\u7a76\u306e\u6700\u524d\u7dda, \u5c71\u672c\u76f4\u6a39, 171-177 (2002). \u30b7\u30e5\u30d7\u30ea\u30f3\u30ac\u30fc\u30fb\u30d5\u30a7\u30a2\u30e9\u30fc\u30af\u6771\u4eac\u682a\u5f0f\u4f1a\u793e, \u6771\u4eac.<\/li>\n
  8. Okayama A, Stuver SO. Long-term follow up of HTLV-I carriers. In: Two decades of adult T cell leukemia and HTLV-I research, ed. Sugamura K, Uchiyama T, Matsuoka M, Kannagi M, pp.127-139(2003). Japan Scientific Societies Press, Tokyo.<\/li>\n<\/ol>\n

    \u3010\u539f\u8457\u3011<\/h4>\n
      \n
    1. Tamura K, Okayama A, Koga K, Sagawa K, Seita M, Tachibana N, Tsuda K. Total body irradiation as a primary treatment for adult T-cell leukemia Japanese. Jpn J Clin Oncol. 1983;13:313-324.<\/li>\n
    2. \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66, \u6960\u6839\u82f1\u53f8, \u6a2a\u7530\u52c9, \u5fd7\u3005\u76ee\u6804\u4e00, \u6d25\u7530\u548c\u77e9, \u4fe3\u91ce\u6d69. \u5bae\u5d0e\u770c\u306b\u304a\u3051\u308b\u30d2\u30c8\uff34\u7d30\u80de\u767d\u8840\u75c5\u30a6\u30a4\u30eb\u30b9\u6297\u4f53\u4fdd\u6709\u72b6\u6cc1. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1984;58:717-722.<\/li>\n
    3. \u6a58\u5ba3\u7965, \u6960\u6839\u82f1\u53f8, \u6a2a\u7530\u52c9, \u5fd7\u3005\u76ee\u6804\u4e00, \u5ca1\u5c71\u662d\u5f66, \u6d25\u7530\u548c\u77e9. \u3064\u3064\u304c\u866b\u75c5\u306e\u8840\u6e05\u5b66\u7684\u8a3a\u65ad\u306b\u304a\u3051\u308b Rickettsia tsutsugamushi\u5f31\u6bd2\u682a\u6297\u539f\u306e\u6709\u7528\u6027. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1984;58:583-589.<\/li>\n
    4. Suzumiya J, Sumiyoshi A, Tamura K, Kawachi J, Okayama A, Tachibana N, Tsuda K, Kuroki Y, Inoue S. Malignant lymphoma in the Miyazaki district: Analysis of 237 biopsy cases. Jpn J Clin Oncol. 1985;15:35-47.<\/li>\n
    5. Tamura K, Nagamine N, Araki Y, Seita M, Okayama A, Kawano K, Tachibana N, Tsuda K, Kuroki Y, Narita H, Inoue S, Suzumiya J, Sumiyoshi A, Aratake Y, Ohtaki S, Torigoe J. A clinical analysis of 33 patients with adult T-cell leukemia (ATL): diagnostic criteria and significance of high- and low-risk ATL. Int J Cancer.1986;37:335-341.<\/li>\n
    6. \u5fd7\u3005\u76ee\u6804\u4e00, \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66, \u77f3\u5d0e\u6df3\u4e09, \u6a2a\u7530\u52c9, \u6d25\u7530\u548c\u77e9. \u5bae\u5d0e\u5730\u65b9\u306e\u6059\u866b\u75c5\u306e\u81e8\u5e8a\u7684\u7814\u7a76. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1987;61:297-302.<\/li>\n
    7. \u5ca1\u5c71\u662d\u5f66, \u6a58\u5ba3\u7965, \u77f3\u5d0e\u6df3\u4e09, \u6a2a\u7530\u52c9, \u5fd7\u3005\u76ee\u6804\u4e00, \u6d25\u7530\u548c\u77e9. \u30d2\u30c8\uff34\u7d30\u80de\u767d\u8840\u75c5\u30a6\u30a4\u30eb\u30b9\uff08\uff28\uff34\uff2c\uff36-\uff29\uff09\u611f\u67d3\u514d\u75ab\u306e\u7814\u7a76\uff08\u2160\uff09\uff0f\u4f4e\u6297\u4f53\u4fa1\u6297\u4f53\u4fdd\u6709\u8005\u306e\u691c\u51fa\u3068\u305d\u306e\u610f\u7fa9. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1987;61:1363-1368.<\/li>\n
    8. \u5ca1\u5c71\u662d\u5f66, \u6a58\u5ba3\u7965, \u6a2a\u7530\u52c9, \u77f3\u5d0e\u6df3\u4e09, \u5fd7\u3005\u76ee\u6804\u4e00, \u6d25\u7530\u548c\u77e9. \u30d2\u30c8\uff34\u7d30\u80de\u767d\u8840\u75c5\u30a6\u30a4\u30eb\u30b9\uff08\uff28\uff34\uff2c\uff36-\uff29\uff09\u611f\u67d3\u514d\u75ab\u306e\u7814\u7a76\uff08\u2161\uff09\uff0f\u30ad\u30e3\u30ea\u30a2\u30fc\u8840\u6e05\u6297\u4f53\u306eRIP, SDS-PAGE\u306b\u3088\u308b\u89e3\u6790. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1987;61:1369-1375.<\/li>\n
    9. Ishizaki J, Okayama A, Tachibana N, Yokota T, Shishime E, Tsuda K, Mueller NE. Comparative diagnostic assay results for detecting antibody to HTLV-I in Japanese blood donor samples: Higher positive rates by particle agglutination assay. J Acquir Immune Defic Syndr. 1988;1:340-345.<\/li>\n
    10. Tachibana N, Okayama A, Ishizaki J, Yokota T, Shishime E, Murai K, Shioiri S, Tsuda K, Essex M, Mueller NE. Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan. Int J Cancer. 1988;42:829-831.<\/li>\n
    11. \u5ca1\u5c71\u662d\u5f66, \u6a58\u5ba3\u7965, \u6a2a\u7530\u52c9, \u77f3\u5d0e\u6df3\u4e09, \u5fd7\u3005\u76ee\u6804\u4e00, \u5b87\u91ce\u4e45\u5149, \u6d25\u7530\u548c\u77e9. \uff21\uff34\uff2c\u60a3\u8005\u8840\u7e01\u8005\u306b\u9ad8\u983b\u5ea6\u306b\u8a8d\u3081\u3089\u308c\u308b\u6297P40x\u6297\u4f53\u5f37\u967d\u6027\u8005. \u533b\u5b66\u306e\u3042\u3086\u307f. 1988;144:573-574.<\/li>\n
    12. Chen YM, Lee T-H, Samuel PK, Okayama A, Tachibana N, Miyoshi I, Papas TS and Essex M. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people. J Virol. 1989;63:4952-4957.<\/li>\n
    13. \u6a2a\u7530\u52c9, \u6a58\u5ba3\u7965, \u5fd7\u3005\u76ee\u6804\u4e00, \u5ca1\u5c71\u662d\u5f66, \u6d25\u7530\u548c\u77e9. \u6059\u866b\u75c5\u306e\u611f\u67d3\u514d\u75ab\u306e\u7814\u7a76.\u3000\u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1989;63:1149-1159.<\/li>\n
    14. \u5ca9\u57ce\u7fa9\u535a, \u6cb3\u91ce\u6e05\u79c0, \u77f3\u5d0e\u6df3\u4e09, \u5ca1\u5c71\u662d\u5f66, \u7530\u6751\u548c\u592b, \u6960\u6839\u82f1\u53f8, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u6210\u4eba\uff34\u7d30\u80de\u767d\u8840\u75c5\u6025\u6027\u5897\u60aa\u306b\u5bfe\u3059\u308bCytoapheresis\u306e\u52b9\u679c\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u81e8\u7240\u3068\u7814\u7a76. 1989;66:157-160.<\/li>\n
    15. Chen YM, Gomez-lucia E, Okayama A, Tachibana N, Lee TH, Mueller NE, Essex M. Antibody profile of early HTLV-I infection. Lancet. 1990;336:1214-1216.<\/li>\n
    16. Murai K, Tachibana N, Shioiri S, Shishime E, Okayama A, Ishizaki J, Tsuda K and Mueller NE. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immune Defic Syndr. 1990;3:1006-1009.<\/li>\n
    17. \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66, \u6751\u4e95\u5e78\u4e00, \u5869\u5165\u91cd\u6b63, \u77f3\u539f\u53f2\u6717, \u5fd7\u3005\u76ee\u6804\u4e00, \u77f3\u5d0e\u6df3\u4e09, \u6d25\u7530\u548c\u77e9. \u5bae\u5d0e\u5730\u65b9\u306eHTLV-I\u6297\u4f53\u967d\u6027\u8005\u306e\u5e74\u4ee4\u5206\u5e03\u306b\u3064\u3044\u3066\u306e\u8840\u6e05\u75ab\u5b66\u7684\u691c\u8a0e. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1990;64:570-574.<\/li>\n
    18. \u6a2a\u7530\u52c9, \u5fd7\u3005\u76ee\u6804\u4e00, \u5ca1\u5c71\u662d\u5f66, \u77f3\u5d0e\u6df3\u4e09, \u6751\u4e95\u5e78\u4e00, \u5869\u5165\u91cd\u6b63, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u8840\u6db2\u60aa\u6027\u75be\u60a3\u306b\u304a\u3051\u308b\u611f\u67d3\u75c7\uff0d\u5f53\u79d1\u306b\u304a\u3051\u308b\u6700\u8fd1\uff11\uff10\u5e74\u9593\u306e\u6557\u8840\u75c7\u306e\u5206\u6790. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1990;64:653-659.<\/li>\n
    19. Okayama A, Chen YM, Tachibana N, Shioiri S, Lee TH, Tsuda K, Essex M. High incidence of antibodies to HTLV-I tax in blood relatives of adult T-cell leukemia patients. J Infect Dis. 1991;163:47-52.<\/li>\n
    20. Welles LS, Mueller NE, Tachibana N, Shishime E, Okayama A, Murai K, Tsuda K. Decreased eosinophil numbers in HTLV-I carriers (letter). Lancet.\u30001991;337:987.<\/li>\n
    21. Okayama A, Korber B, Chen YM, Allan J, Lee TH, Shioiri S, Tachibana N, Tsuda K, Mueller NE, McLane FM, Maayan S, Orgad S, Ernst J, Marlink R, Essex M. Unusual pattern of antibodies to human T-cell leukemia virus type-I in family members of adult T-cell leukemia patients. Blood. 1991;78:3323-3329.<\/li>\n
    22. Korber B, Okayama A, Donnerlly R, Tachibana N, Essex M. Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol. 1991;65:5471-5476.<\/li>\n
    23. Chen YM, Okayama A, Lee TH, Tachibana N, Mueller NE, Essex M. Sexual transmission of human T-cell leukemia virus type 1 associated the presence of anti-Tax antibody. Proc Natl Acad Sci U S A. 1991;88:1182-1186.<\/li>\n
    24. Murai K, Tachibana N, Okayama A, Shishime E, Tsuda K, Oshikawa T. Sensitivity of polymerase chain reaction assay for Rickettsia tsutsugamushi in patient’s blood samples. Microbiol Immunol. 1992;36:1145-1153.<\/li>\n
    25. Tachibana N, Okayama A, Ishihara S, Shioiri S, Murai K, Tsuda K, Goya N, Matsuo Y, Essex M, Stuver SO, Mueller NE. High HTLV-I proviral DNA level associated with abnormal lymphocytes in peripheral blood from asymptomatic carriers. Int J Cancer. 1992;51:593-595.<\/li>\n
    26. Ishihara S, Tachibana N, Okayama A, Murai K, Tsuda K, Mueller NE. Successful graft of HTLV-I-transformed human T-cells(MT-2) in severe combined immunodeficiency mice treated with anti-asialo GM-I antibody. Jpn J Cancer Res. 1992;83:320-323.<\/li>\n
    27. Stuver SO, Tachibana N, Okayama A, Romano F, Yokota T, Mueller NE. Determinants of HTLV-I sero prevalence in Miyazaki prefecture, Japan: A cross-sectional study. J Acquir Immune Defic Syndr. 1992;5:12-18.<\/li>\n
    28. Shioiri S, Tachibana N, Okayama A, Ishihara S, Tsuda K, Essex M, Stuver SO, Mueller NE. Analysis of anti-tax antibody of HTLV-I carriers in endemic area in JAPAN. Int J Cancer. 1993;53:1-4.<\/li>\n
    29. Stuver SO, Tachibana N, Okayama A, Shioiri S, Tsunetoshi Y, Tsuda K, Mueller NE. Heterosexual transmission of human T cell leukemia\/lymphoma virus type 1 among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis. 1993;167:57-65.<\/li>\n
    30. Welles SL, Tachibana N, Okayama A, Ishizaki J, Mueller NE. Changes in hematologic parameters among Japanese HTLV-I carriers. J Acquir Immune Defic Syndr.1994;7:92-97.<\/li>\n
    31. Ishihara S, Okayama A, Horinouchi H, Shioiri S, Murai K, Kubota T, Yamashita R, Tachibana N, Tsubouchi H, Stuver SO, Mueller NE. Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells. J Acquir Immune Defic Syndr. 1994;7:199-203.<\/li>\n
    32. Welles SL, Tachibana N, Okayama A, Murai K, Shioiri S, Sagawa K, Katagiri K, Mueller NE. The distribution of T-cell subsets among HTLV-I carriers in Japan. J Acquir Immune Defic Syndr.1994;7:509-516.<\/li>\n
    33. Welles SL, Tachibana N, Okayama A, Shioiri S, Ishihara S, Murai K, Mueller NE. Decreased reactivity to PPD among HTLV-I carriers in relation to virus and hematologic status. Int J Cancer. 1994;56:337-340.<\/li>\n
    34. Okayama A, Maruyama T, Tachibana N, Hayashi K, Kitamura T, Mueller NE, Tsubouchi H. Increased prevalence of HTLV-I infection in patients with hepatocellular carcinoma associated with hepatitis C virus. Jpn J Cancer Res. 1995;86:1-4.<\/li>\n
    35. Chou KS, Okayama A, Tachibana N, Lee TH, Essex M. Nucleotide sequence analysis of a full-length human T-cell leukemia virus type I from adult T-cell leukemia cells: A prematurely terminated pX open reading frame II. Int J Cancer. 1995;60:701-706.<\/li>\n
    36. Murai K, Okayama A, Horinouchi H, Oshikawa T, Tachibana N, Tsubouchi H. Eradication of Rickettsia tsutsugamushi from patients’ blood by chemotherapy, as assessed by the polymerase chain reaction. Am J Trop Med Hyg. 1995;52:325-327.<\/li>\n
    37. \u5ca1\u5c71\u662d\u5f66, \u4e38\u5c71\u82f1\u6674, \u6cb3\u91ce\u9435, \u5317\u6751\u4ea8, \u5fd7\u6469\u5b5d, \u6797\u514b\u88d5, \u4e38\u5c71\u4fca\u535a, \u576a\u5185\u535a\u4ec1. \uff23\u578b\u539f\u767a\u6027\u809d\u764c\u306b\u9ad8\u983b\u5ea6\u306b\u8a8d\u3081\u3089\u308c\u308bHTLV-I\u611f\u67d3\u306e\u610f\u7fa9. \u81e8\u5e8a\u3068\u7814\u7a76. 1995;72:2538-2540.<\/li>\n
    38. Ishihara S, Okayama A, Nagatomo Y, Murai K, Yamashita R, Okamoto M, Shima T, Sasaki T, Mueller NE, Tachibana N, Tsubouchi H. Enhanced engraftment of HTLV-I-infected human T cells in severe combined immunodeficiency mice by anti-asialo GM-1 antibody treatment. Microbiol Immunol. 1996;40:39-44.<\/li>\n
    39. Horinouchi H, Murai K, Okayama A, Nagatomo Y, Tachibana N, Tsubouchi H. Genotypic identification of Rickettsia tsutsugamushi by restriction fragment length polymorphism analysis of DNA amplified by the polymerase chain reaction. Am J Trop Med Hyg. 1996;54:647-651.<\/li>\n
    40. Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Tabor E. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer. 1996;67:35-37.<\/li>\n
    41. Chou KS, Okayama A, Su IJ, Lee TH, Essex M. Preferred nucleotide sequence at the integration target site of human T-cell leukemia virus type I from patients with adult T-cell leukemia. Int J Cancer. 1996;65:20-24.<\/li>\n
    42. Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type I carriers in Miyazaki, Japan. J Infect Dis. 1996;173:584-591.<\/li>\n
    43. Hisada M, Mueller NE, Welles LS, Okayama A. Re: \u201dRisk factors for non-Hodgikin\u2019s lymphomas in acquired immunodeficiency syndrome(AIDS)\u201d. Am J Epidemiol. 1997;146:681-682.<\/li>\n
    44. Okayama A, Tachibana N, Ishihara S, Nagatomo Y, Murai K, Okamoto M, Shima T, Sagawa K, Tsubouchi, H., Stuver SO, Mueller NE. Increased expression of interleukin-2 receptor \u03b1 on peripheral blood mononuclear cells in HTLV-I tax\/rex mRNA-positive asymptomatic carriers. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:70-75.<\/li>\n
    45. Tanaka K, Stuver SO, Ikematsu H, Okayama A, Tachibana N, Hirohata T, Kashiwagi S, Tsubouchi H, Mueller NE. Heterosexual transmission of hepatitis C virus among married couples in southwestern Japan. Int J Cancer. 1997;72:50-55.<\/li>\n
    46. Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, Muller NE, Takatsuki K, Matsuoka M. Persistent clonal proliferation of human T-cell lymphotropic virus type I -infected cells in vivo. Cancer Res. 1997;57:4862-4867.<\/li>\n
    47. Horinouchi H, Murai K, Okayama A, Nagatomo Y, Tsubouchi H, Tachibana N. Prevelence of genotypes of Orientia tsutsugamushi in patients with scrub typhus in Miyazaki prefecture. Microbiol Immunol. 1997;41:503-507.<\/li>\n
    48. Yamashita R, Tachibana N, Murai K, Okayama A, Tsubouchi H. Detection of polyanion-restricted anti-histone antibodies in patients with systemic lupus erythematosus. Intern Med. 1997;36:781-786.<\/li>\n
    49. Hisada M, Shima T, Okayama A, Mueller NE, Tsubouchi H, Stuver SO. Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HTLV-I carriers in Japan. J Acquir Immune Defic Syndr. 1998;19:421-425.<\/li>\n
    50. Shioiri S, Stuver SO, Okayama A, Murai K, Shima T, Tachibana N, Tsubouchi H, Essex M, Mueller NE. Intrafamilial transmission of HTLV- I and its association with anti-tax antibody in an endemic population in Japan. Int J Cancer. 1998;75:15-18.<\/li>\n
    51. Hisada M, Okayama A, Tachibana N, Stuver SO, Spiegelman DL, Tsubouchi H, Mueller NE. Predictors of level of circulating abnormal lymphocytes among human T-lymphotropic virus type I carriers in Japan. Int J Cancer. 1998;77:188-192.<\/li>\n
    52. Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers of human T-cell leukemia among cariers of human T-lymphotropic virus type I. Blood. 1998;92:3557-3561.<\/li>\n
    53. Suzuki M, Dezzutti SC, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Lal BR. Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals. Clin Diagn Lab Immunol. 1999;6:713-717.<\/li>\n
    54. Hisada M, Stuver SO, Okayama A, Mueller NE. Gender difference in skin reactivity to purified protein derivative among carriers of HTLV-I in Japan. J Acquire Immune Defic Syndr. 1999;22:302-307.<\/li>\n
    55. Etoh K, Yamaguchi K, Tokudome S, Watanabe T, Okayama A, Stuver SO, Mueller NE, Takatsuki K, Matsuoka M. Rapid quantification of HTLV- I provirus load : Detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Int J Cancer. 1999;81:859-864.<\/li>\n
    56. Abtahi A, Mueller NE, Okayama A, Stuver SO. Lack of evidence for a role of HTLV- I infection in the occurrence of subclinical HAM\/TSP in the Miyazaki cohont study. J Acquire Immune Defic Syndr Hum.Retrovirol. 2000;24:86-87.<\/li>\n
    57. Stuver SO, Pinto BC, Okayama A, Mueller NE. Reply to a letter to editor. J Infect Dis. 2000;182:379-380.<\/li>\n
    58. Stuver SO, Tanaka K, Ikematsu H, Okayama A, Tachibana N, Hirohata T, Kashiwagi S, Tsubouchi H, Mueller NE. Heterosexual transmission of hepatitis C virus among married couples in southwestern Japan. Int J Cancer. 2000;88:833-834.<\/li>\n
    59. Boschi-Pinto C, Stuver SO, Okayama A, Trichopouloas D, Oray EJ, Tsubouchi H. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis. 2000;181:35-41.<\/li>\n
    60. Okayama A, Sherri SO, Iga M, Masayuki O, Mueller NE, Matsuoka M, Yamaguchi K, Tachibana N, Tsubouchi H. Seqential charge of virus markers in seroconverters with community-acquried infection of human T lymphotropic virus type I. J Infect Dis. 2001;183:1031-1037.<\/li>\n
    61. Hisada M, Okayama A, Spiegelman D, Mueller NE, Stuver SO. Sex-specific mortality from adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Int J Cancer. 2001;91:497-499.<\/li>\n
    62. Arduino JM, Stuver SO, Spiegelman D, Okayama A, Tabor E, Yu MW, Kohara M, Tsubouchi H, Mueller NE. Assessment of makers of hepatitis C virus infection in a Japanese adult population. J Infect Dis. 2001;184:1229-1235.<\/li>\n
    63. Okayama A, Stuver SO, Tabor E, Tachibana N, Kohara M, Mueller NE, Tsubouchi H. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepatitis. 2002;9:43-51.<\/li>\n
    64. Iga M, Okayama A, Stuver SO, Matsuoka M, Mueller NE, Aoki M, Mitsuya H, Tachibana N, Tsubouchi H. Genetic evidence of transmission of human T-lymphotropic virus type-I between spouses. J Infect Dis. 2002;185:691-695.<\/li>\n
    65. Koiwa T, Hamano-Usami A, Ishida T, Okayama A, Yamaguchi K, Kamihira S, Watanabe T. 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol. 2002;76:18,9389-9397.<\/li>\n
    66. Ishizaki J, Okayama A, Kuroki M, Tsubouchi H. Detection of human T-lymphotropic virus typeI (HTLV-I) infection during coculture of HTLV-I infected and uninfected cells using inverse long PCR. Intervirology. 2002;45:164-171.<\/li>\n
    67. Iga M, Matsuda Z, Okayama A, Sugiura W, Hashida S, Morishita K, Nagai Y, Tsubouchi H. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J. Virol Methods. 2002;106:25-37.<\/li>\n
    68. Kuroki M, Okayama A, Nakamura S, Sasaki T, Murai K, Shiba R, Shinohara M, Tsubouchi H. Detection of maternal-fetal microchimerism in the inflammatory lesions of patients with Sjogren’s syndrome. Ann Rheum Dis. 2002;61:12,1041-1046.<\/li>\n
    69. \u885b\u85e4\u7fa9\u52dd, \u5927\u6a4b\u5341\u4e5f, \u4eca\u4e95\u7950\u4e00, \u539a\u6771\u7be4\u751f, \u677e\u672c\u7fa9\u4e5f, \u5bae\u6b66\u90a6\u592b, \u85e4\u8107\u5efa\u4e45, \u897f\u7f8e\u548c, \u5ca1\u5c71\u662d\u5f66, \u7d0d\u5149\u5f18, \u5927\u548c\u7530\u64cd, \u677e\u5c3e\u6e05\u4e00, \u4e21\u89d2\u5700\u7537, \u91cd\u677e\u79c0\u4e00, \u5317\u5ddd\u7167\u7537. \u30d5\u30a1\u30d6\u30ea\uff0d\u75c5\u60a3\u8005\u306b\u5bfe\u3059\u308b\u03b1-\u30ac\u30e9\u30af\u30c8\u30b7\u30c0\uff0d\u30bcA\u88dc\u5145\u7642\u6cd5\u306e\u591a\u65bd\u8a2d\u81e8\u5e8a\u8a66\u9a13\u6210\u7e3e. \u5c0f\u5150\u79d1\u81e8\u5e8a. 2003;56:1,133-143.<\/li>\n
    70. \u5ca1\u5c71\u662d\u5f66, \u4e45\u51a8\u6728\u5eb8\u5b50. \u30ea\u30f3\u30d5\u30a9\uff0d\u30de\u6cbb\u7642\u306b\u304a\u3051\u308b\u5c55\u671b. \u30c7\u30eb\u30de. 2003;80:67-73.<\/li>\n
    71. Dewan MZ, Terashima K, Taruishi M, Hasegawa H, Ito M, Tanaka Y, Mori N, Sata T, Koyanagi Y, Maeda M, Kubuki Y, Okayama A, Fujii M, Yamamoto N. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID\/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J Virol. 2003;77:9,5286-5294.<\/li>\n
    72. Raker CA, Tabor E, Okayama A, Yu MW, Kohara M, Mueller NE, Tsubouchi H, Stuver SO. HCV core antigen as an alternative to NAT to detect HCV viremia. Transfusion. 2004;44:307-308.<\/li>\n<\/ol>\n

      \u3010\u75c7\u4f8b\u5831\u544a\uff08\u8ad6\u6587\uff09\u3011<\/h4>\n
        \n
      1. \u5ca1\u5c71\u662d\u5f66, \u7530\u6751\u548c\u592b, \u6a2a\u7530\u52c9, \u6960\u6839\u82f1\u53f8, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u5168\u8eab\u7167\u5c04\u7642\u6cd5\u306b\u3088\u308a\u5bdb\u89e3\u3057\u3048\u305f\u6210\u4eba\uff34\u7d30\u80de\u767d\u8840\u75c5\u306e\uff11\u4f8b. \u81e8\u5e8a\u8840\u6db2. 1984;25:188-192.<\/li>\n
      2. \u6751\u4e95\u5e78\u4e00, \u77f3\u5d0e\u6df3\u4e09, \u5ca9\u57ce\u7fa9\u535a, \u5ca1\u5c71\u662d\u5f66, \u4e2d\u6751\u6771\u6a39, \u4e38\u5c71\u4fca\u535a, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u767a\u4f5c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f\u75c7\u306e\u7d4c\u904e\u4e2d\u306b\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u306e\u75c5\u50cf\u3092\u5448\u3057\u305f\uff11\u4f8b. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c. 1985;9:108-113.<\/li>\n
      3. \u5ca1\u5c71\u662d\u5f66, \u4e2d\u6751\u6771\u6a39, \u4e38\u5c71\u4fca\u535a, \u6797\u514b\u88d5, \u5317\u6751\u4ea8, \u77f3\u91ce\u7530\u5409\u5f18, \u6a2a\u7530\u52c9, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u7009\u8840\u7642\u6cd5\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u6669\u767a\u751f\u76ae\u819a\u30dd\u30eb\u30d5\u30a3\u30ea\u30f3\u75c7\u306e\u4e00\u4f8b. \u809d\u81d3. 1986;27:100-105.<\/li>\n
      4. \u6cb3\u91ce\u6e05\u79c0, \u5b87\u91ce\u4e45\u5149, \u795e\u5c3e\u91cd\u5247, \u5ca1\u5c71\u662d\u5f66, \u6a2a\u7530\u52c9, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9, \u53e4\u8cc0\u5b5d, \u7a0e\u6240\u5e78\u4e00\u90ce, \u4f4f\u5409\u662d\u4fe1. \u9ec4\u8272\u30d6\u30c9\u30a6\u7403\u83cc\u306b\u3088\u308b\u591a\u81d3\u5668\u81bf\u760d\u3092\u8a8d\u3081\u305f\u809d\u786c\u5909,\u7cd6\u5c3f\u75c5\u306e\u4e00\u5256\u691c\u4f8b.\u3000\u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c. 1986;10:102-106.<\/li>\n
      5. \u6a58\u5ba3\u7965, \u5fd7\u3005\u76ee\u6804\u4e00, \u6a2a\u7530\u52c9, \u5ca1\u5c71\u662d\u5f66, \u77f3\u5d0e\u6df3\u4e09, \u6751\u4e95\u5e78\u4e00, \u5869\u5165\u91cd\u6b63, \u6d25\u7530\u548c\u77e9, \u62bc\u5ddd\u9054\u5df3. \u4e5d\u5dde\u5730\u65b9\u3067\u767a\u751f\u3057\u305f\u7d05\u6591\u71b1\u30ea\u30b1\u30c3\u30c1\u30a2\u75c7\u306e\uff12\u4f8b. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 1987;61:1166-1172.<\/li>\n
      6. \u5c71\u4e0b\u826f\u4e09, \u5fd7\u3005\u76ee\u6804\u4e00, \u77f3\u5c71\u96c4\u4e00\u90ce, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u30b7\u30a7\u30fc\u30b0\u30ec\u30f3\u75c7\u5019\u7fa4\u3068\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u3092\u5408\u4f75\u3057\u305f\u6162\u6027\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1\u306e\uff11\u75c7\u4f8b. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c. 1991;15:316-320.<\/li>\n
      7. \u7389\u7f6e\u6607, \u5ca1\u5c71\u662d\u5f66, \u5ca9\u57ce\u7fa9\u535a, \u677e\u5ca1\u5747, \u5b87\u91ce\u4e45\u5149, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u9577\u671f\u9593\u306e\u4e2d\u5fc3\u9759\u8108\u30ab\u30c6\u30fc\u30c6\u30eb\u7559\u7f6e\u306b\u3088\u308a\u30ab\u30f3\u30b8\u30c0\u8840\u75c7\u3092\u304d\u305f\u3057,fluconazole\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u306e\uff11\u4f8b. \u816b\u760d\u3068\u611f\u67d3. 1991;4:357-360.<\/li>\n
      8. \u677e\u5ca1\u5747, \u5b87\u91ce\u4e45\u5149, \u5ca1\u5c71\u662d\u5f66, \u524d\u7530\u5b8f\u4e00, \u7389\u7f6e\u6607, \u9234\u6728\u658e\u738b, \u4e45\u51a8\u6728\u5eb8\u5b50, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9, \u6cb3\u91ce\u6e05\u79c0,\u77f3\u5d0e\u6df3\u4e09. \u5f53\u79d1\u306b\u304a\u3051\u308b\u6210\u4eba\u6025\u6027\u767d\u8840\u75c5\u9577\u671f\u751f\u5b58\u4f8b\u306e\u691c\u8a0e. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c. 1992;16:57-61.<\/li>\n
      9. \u6a4b\u53e3\u5bb9\u5b50, \u5ca1\u5c71\u662d\u5f66, \u524d\u7530\u5b8f\u4e00, \u677e\u5ca1\u5747, \u5b87\u91ce\u4e45\u5149, \u6a58\u5ba3\u7965. Clindamycin\u304c\u6709\u52b9\u3067\u3042\u3063\u305fClostridium perfringens\u6557\u8840\u75c7\u306e1\u4f8b. SCOPE. 1992;31:12.<\/li>\n
      10. \u5800\u4e4b\u5185\u5bff\u4eba, \u5ca1\u672c\u525b, \u5ca1\u5c71\u662d\u5f66, \u4e38\u5c71\u4fca\u535a, \u6a58\u5ba3\u7965, \u6d25\u7530\u548c\u77e9. \u7279\u767a\u6027\u6c17\u8179\u306e\uff11\u4f8b. \u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u96d1\u8a8c. 1993;82:113-114.<\/li>\n
      11. \u5c0f\u6fa4\u4ec1\u96c4, \u5c71\u7e23\u7f8e\u5948\u5b50, \u9577\u53cb\u82f1\u535a, \u91cd\u5e73\u6b63\u6587, \u9db4\u7530\u548c\u4ec1, \u6817\u6797\u5fe0\u4fe1, \u5c0f\u539f\u5065\u4e00, \u524d\u7530\u5b8f\u4e00,\u5ca1\u5c71\u662d\u5f66, \u4e95\u4e0a\u8f1d\u5f66, \u6cb3\u91ce\u6b63. \u9ad8\u30ab\u30eb\u30b7\u30a6\u30e0\u8840\u75c7\u3092\u5408\u4f75\u3057\u8457\u660e\u306a\u9aa8\u7834\u58ca\u50cf\u3092\u5448\u3057\u305f\u9aa8\u539f\u767a\u60aa\u6027\u30ea\u30f3\u30d1\u816b\u306e\uff11\u4f8b. \u5bae\u5d0e\u770c\u533b\u5e2b\u4f1a\u533b\u5b66\u4f1a\u8a8c. 1994;18:310-313.<\/li>\n
      12. Nagatomo Y, Uno H, Maeda K, Matsuoka H, Tsuruda T, Okayama A, Tachibana N, Tsubouchi H. Bulky Plasmacytoma of the Bone with Intracranial Invasion. Intern Med. 1994;33:376-379.<\/li>\n
      13. Kodama M, Matsuoka H, Maeda K, Suzuki M, Okayama A, Uno H, Tachibana N, Komada N, Kouno M, Ohshima K. Smoldering adult T-Cell leukemia with B-cell lymphoma and early gastric cancer. Intern Med. 1995;34:118-121.<\/li>\n
      14. Doi S, Murai K, Okayama A, Shigehira M, Nakama T, Ishihara S, Yamashita R, Marutsuka K, Sumiyoshi A, Amano M, Inoue S, Tsubouchi H. Familial Mediterranean fever with erythema nodosum in an adult. Jpn J Rheumatol. 1996;6:147-154.<\/li>\n
      15. Sasaki T, Okayama A, Eizuru Y, Murai K, Matsuoka H, Uno H, Minamishima Y, Kataoka H, Koono M, Matsuura Y, Nao-i N, Sawada A, Tachibana N, Tsubouchi H. Progressive retinitis-encephalitis due toganciclovir-resistant cytomegalovirus associated with aplastic anemia. Intern Med. 1997;36:375-379.<\/li>\n
      16. \u9ed2\u6728\u660c\u5e78, \u5ca1\u5c71\u662d\u5f66, \u6851\u7530\u525b, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u4f0a\u8cc0\u7766\u4e86, \u5ca1\u672c\u5c06\u5e78, \u677e\u5c71\u5e79\u592a\u90ce, \u6751\u4e95\u5e78\u4e00, \u576a\u5185\u535a\u4ec1. \u4e2d\u67a2\u795e\u7d4c\u30eb\u30fc\u30d7\u30b9\u69d8\u75c7\u72b6\u3092\u5448\u3057Prednisolone\u3068Cyclophosphamide\u306e\u4f75\u7528\u7642\u6cd5\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\u6df7\u5408\u6027\u7d50\u5408\u7d44\u7e54\u75c5\u306e1\u75c7\u4f8b. \u30ea\u30a6\u30de\u30c1. 2000;40:627-632.<\/li>\n
      17. Nagatomo Y, Okayama A, Murai K, Sasaki T, Kuroki M, Tanaka G, Iga M, Kai Y, Tsubouchi H. Successful treatment using high-dose intravenous immunogloblin in a patient with rapidly progressive interstitial pneumonia associated with dermatomyositis. Mod Rheumatol. 2000;10:165-168.<\/li>\n
      18. \u5ca1\u672c\u5c06\u5e78, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u95a2\u5c4b\u4eae, \u7247\u5ca1\u5bdb\u5e78, \u98ef\u91ce\u82f1\u89aa, \u5e38\u5ca1\u82f1\u5f18, \u585a\u539f\u6b63\u4eba, \u576a\u5185\u535a\u4ec1. \u809d\u813e\u306b\u591a\u767a\u6027\u7d50\u7bc0\u6027\u75c5\u5909\u3092\u304d\u305f\u3057\u305f\u5168\u8eab\u6027\u306d\u3053\u3072\u3063\u304b\u304d\u75c5\u306e\u6210\u4eba\u4f8b. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 2001;75:499-503.<\/li>\n
      19. \u7530\u4e2d\u5f26\u4e00, \u9577\u53cb\u5b89\u5f18, \u7532\u6590\u6cf0\u6587, \u677e\u5c71\u5e79\u592a\u90ce, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u6cbb\u7642\u306b\u3088\u308a\u7570\u306a\u308b\u81e8\u5e8a\u7d4c\u904e\u3092\u793a\u3057\u305f\u30de\u30a4\u30b3\u30d7\u30e9\u30ba\u30de\u80ba\u708e\u306e\u4e00\u5375\u6027\u59c9\u59b9\u4f8b. \u611f\u67d3\u75c7\u5b66\u96d1\u8a8c. 2002;76:12,1040-1044.<\/li>\n<\/ol>\n

        \u3010\u7dcf\u8aac\u3011<\/h4>\n
          \n
        1. \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66. \u6210\u4eba\uff34\u7d30\u80de\u767d\u8840\u75c5\uff08\uff21\uff34\uff2c\uff09\u306e\u73fe\u6cc1. \u5bae\u5d0e\u770c\u5185\u79d1\u533b\u4f1a\u8a8c. 1986;22-26.<\/li>\n
        2. \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66. \u65e5\u548c\u898b\u611f\u67d3\u3068\u305d\u306e\u8981\u56e0. \u85ac\u5c40. 1987;38:1455-1459.<\/li>\n
        3. Mueller NE, Okayama A, Stuver SO, Tachibana N. Findings from the Miyazaki cohort study. J Acquir Immune Defic Syndr. 1996;13:52-57.<\/li>\n
        4. \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u9ad8\u9f62\u8005\u306e\u9662\u5185\u611f\u67d3\u75c7. \u8001\u5316\u3068\u75be\u60a3. 1998;11:92-93.<\/li>\n
        5. Dzik WH, Okayama A. Can blood transfusion transmit disease-producing genes Transfusion. 1999;39:795-800.<\/li>\n
        6. \u5ca1\u5c71\u662d\u5f66. \u6210\u4eba\u306e\u30ef\u30af\u30c1\u30f3\u6295\u4e0e. Medicina. 1999;36:1955-1957.<\/li>\n
        7. \u5ca1\u672c\u5c06\u5e78, \u9577\u53cb\u5b89\u5f18, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66. SS\u306b\u304a\u3051\u308b\u80ba\u75c5\u5909\u306e\u8a3a\u7642. \u30ea\u30a6\u30de\u30c1\u79d1. 2000;23:52-57.<\/li>\n
        8. \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66. \u30ea\u30b1\u30c3\u30c1\u30a2\u611f\u67d3\u75c7\u3000\u30c4\u30c4\u30ac\u30e0\u30b7\u75c5. \u65e5\u672c\u81e8\u5e8a. 2003;61:500-504.<\/li>\n
        9. \u6a58\u5ba3\u7965, \u5ca1\u5c71\u662d\u5f66. \u30c4\u30c4\u30ac\u30e0\u30b7\u75c5. \u7dcf\u5408\u81e8\u5e8a. 2003;52:\u5897\u520a,453-458.<\/li>\n<\/ol>\n

          –<\/p>\n

          \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

          B. \u767a\u8868<\/h3>\n

          \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/h4>\n
            \n
          1. Okayama A, Tachibana N, Ishihara S, Shioiri S, Tsuda K, Mueller NE. High level of HTLV-1 proviral DNA associated with abnormal lymphocytes in peripheral blood from asymptomatic carriers. 5th International.Conference on Human Retrovirology: HTLV. 1992.<\/li>\n
          2. \u5ca1\u5c71\u662d\u5f66. \u611f\u67d3\u75c7\u9818\u57df\u306b\u304a\u3051\u308b\u907a\u4f1d\u5b50\u5897\u5e45\u6cd5\u306e\u5fdc\u7528 \uff0dHTLV-1\u3092\u4e2d\u5fc3\u3068\u3057\u3066\uff0d. \u7b2c16\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a. 1993.<\/li>\n
          3. Mueller NE, Marshall L, Stuver SO, Tachibana N, Tsubouchi H, Okayama A. Increased mortality from virus-associated malignancies other than ATL among HTLV-1 carriers in the Miyazaki cohort study. 7th International. Conference on Human Retrovirology:HTLV. 1995.<\/li>\n
          4. \u6c5f\u85e4\u5065\u4e00\u90ce, \u677e\u5ca1\u96c5\u96c4, \u7530\u5bae\u8c9e\u5b8f, \u5c71\u53e3\u4e00\u6210, \u5ca1\u5c71\u662d\u5f66, \u9ad8\u6708\u6e05, Mueller NE. HTLV-1\u611f\u67d3\u7d30\u80de\u306e\u30af\u30ed\u30fc\u30f3\u6027\u5897\u6b96. \u7b2c55\u56de \u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a. 1996.<\/li>\n
          5. Okayama A, Stuver SO, Tabor E, Tachibana N, Tsubouchi H, Kohara M, Mueller NE. Sequential change of viral markers in hepatitis C virus seroconverters :A community based study. 2nd International. Conference on Therapies for Viral Hepatitis. 1997.<\/li>\n
          6. Okayama A, Stuver SO, Okamoto M, Tachibana N, Matsuoka M, Yamaguchi K, Eto K, Mueller NE and Tsubouchi H. Sequential changes of viral markers in HTLV-1 seroconverters in Japan. 8th International. Conference of Human Retrovirology. 1997.<\/li>\n
          7. Etoh K, Yamaguchi K, Watanabe T, Okayama A, Ono A, Mochizuki M, Mueller NE, Takatsuki K, Matsuoka M. Quantitative analysis of HTLV-1 provirus by Amplisensor. 8th International. Conference of Human Retrovirology. 1997.<\/li>\n
          8. \u5ca1\u672c\u5c06\u5e78, \u9577\u53cb\u5b89\u5f18, \u5c71\u4e0b\u826f\u4e09, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. HTLV-1\u6297\u4f53\u967d\u6027\u30b7\u30a7\u30fc\u30b0\u30ec\u30f3\u75c7\u5019\u7fa4\u60a3\u8005\u306b\u304a\u3051\u308b\u611f\u67d3\u7d30\u80de\u30af\u30ed\u30ca\u30ea\u30c6\u30a3\u30fc\u306e\u89e3\u6790\uff0e \u7b2c41\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 1997.<\/li>\n
          9. \u5ca1\u672c\u5c06\u5e78, \u5ca1\u5c71\u662d\u5f66, \u9577\u53cb\u5b89\u5f18, \u4f50\u3005\u6728\u9686, \u677e\u5c71\u5e79\u592a\u90ce, \u9ed2\u6728\u660c\u5e78, \u6751\u4e95\u5e78\u4e00, \u576a\u5185\u535a\u4ec1. \u9593\u8cea\u6027\u80ba\u75c5\u5909\u3092\u4f34\u3063\u305fHTLV-1\u6297\u4f53\u967d\u6027\u30b7\u30a7\u30fc\u30b0\u30ec\u30f3\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u611f\u67d3\u7d30\u80de\u306e\u5f79\u5272. \u7b2c42\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 1998.<\/li>\n
          10. Okayama A, Hisada M, Stuver SO, OkamotoM, Kawano K, Tachibana N, Matsuoka M, Yamaguchi K, Etoh K, Mueller NE, Tsubouchi H. HTLV-1 markers in three carriers who eventually developed adult T-cell leukemia in the Miyazaki cohort study. 9th International. Conference on Human Retrovirology\uff1aHTLV and related viruses. 1999.<\/li>\n
          11. \u9ed2\u6728\u660c\u5e78, \u5ca1\u5c71\u662d\u5f66, \u5ca1\u672c\u5c06\u5e78, \u9577\u53cb\u5b89\u5f18, \u6751\u4e95\u5e78\u4e00, \u7be0\u539f\u6b63\u5fb3, \u829d\u826f\u7950, \u4e2d\u6751\u8aa0\u53f8. HTLV-1\u6297\u4f53\u967d\u6027\u30b7\u30a7\u30fc\u30b0\u30ec\u30f3\u75c7\u5019\u7fa4\u60a3\u8005\u306b\u304a\u3051\u308b\u30de\u30a4\u30af\u30ed\u30ad\u30e1\u30ea\u30ba\u30e0\u306e\u95a2\u4e0e. \u7b2c44\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2000.<\/li>\n
          12. Mueller NE, Okayama A, Stuver SO, Hisada M. The blind epidemiologists and the elephant\uff1a The natural history of HTLV-1 infection. 10th International. Conference on Human Retrovirology:HTLV and related viruses. 2001.<\/li>\n
          13. Okayama A, Stuver SO, Ishizaki J, Murai K, Suzuki M, Kubuki Y, Tachibana N, Matsuoka M, Yamaguchi K, Etoh K, Mueller NE, Tsubouchi H. HTLV-1 proviral DNA load in carriers as a risk factor for adult T-cell leukemia. 10th International conference on human retrovirology: HTLV and related viruses. 2001.<\/li>\n
          14. Powlish K, Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE. Mortality associated with human T-lymphotropic virus type-1 infection in the Miyazaki Cohort Study, Japan. 10th International Conference on human retrovirology:HTLV and related viruses. 2001.<\/li>\n
          15. Kubuki Y, Suzuki M, Okayama A, Stuver SO, Ishizaki J, Murai K, Mueller NE, Tsubouchi H. Telomerase activity in adult T-cell leukemia. 10th International Conference on human retrovirology: HTLV and related viruses. 2001.<\/li>\n
          16. Iga M, Okayama A, Stuver S, Matsuoka M, Aoki M, Mitsuya H, Mueller NE, Tachibana N, Murai K, Tsubouchi H. Genetic evidence of transmission of human T-cell lymphotropic virus type I between spouses. 10th International Conference on human retrovirology: HTLV and related viruses. 2001.<\/li>\n
          17. Birmann B, Mueller NE, Okayama A, Tachibana N, Tsubouchi H, Stuver S. Type 1\/type2 cytokine inbalance in asymptomatic carriers of human T-lymphotropic virus type 1 in the Miyazaki cohort syudy. 10th International Conference on human retrovirology: HTLV\u3000and related viruses. 2001.<\/li>\n
          18. \u5ca1\u5c71\u662d\u5f66. HTLV-1\u30ad\u30e3\u30ea\u30a2\u306e\u9577\u671f\u30d5\u30a9\u30ed\uff0d\u30a2\u30c3\u30d7. \u65e5\u672c\u764c\u5b66\u4f1a\u30df\u30cb\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\u306e\u30a6\u30a4\u30eb\u30b9\u75c5\u56e0\u767a\u898b\u304b\u308920\u5e74\u300d. 2001.<\/li>\n
          19. \u4f0a\u8cc0\u7766\u4e86, \u5ca1\u5c71\u662d\u5f66, \u677e\u5c71\u5e79\u592a\u90ce, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u576a\u5185\u535a\u4ec1, \u6a4b\u7530\u8aa0\u4e00, \u68ee\u4e0b\u548c\u5f18. Identification\u3000of a novel\u3000\u03b1-galactosidase A mutation in a Japanese case of Fabry dissease with systemic inflammatory findings. 10th International Congress of Human Genetics. 2001.<\/li>\n
          20. \u4f0a\u8cc0\u7766\u4e86, \u5ca1\u5c71\u662d\u5f66, \u677e\u5c71\u5e79\u592a\u90ce, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u576a\u5185\u535a\u4ec1, \u6a4b\u7530\u8aa0\u4e00, \u68ee\u4e0b\u548c\u5f18. \u767a\u71b1\u3092\u4e3b\u75c7\u72b6\u3068\u3059\u308bFabry\u75c5\u60a3\u8005\u306e\u03b1-galactosidase\u907a\u4f1d\u5b50\u65b0\u898f\u5909\u7570\uff08G430\uff09\u306e\u540c\u5b9a\u3068\u6a5f\u80fd\u89e3\u6790. \u7b2c98\u56de\u65e5\u672c\u5185\u79d1\u5b66\u4f1a. 2001.<\/li>\n
          21. \u576a\u5185\u76f4\u5b50, \u7532\u6590\u6cf0\u6587, \u84ee\u6c60\u609f, \u4f0a\u8cc0\u7766\u4e86, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00,\u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u8457\u660e\u306a\u80c6\u9053\u7cfb\u9175\u7d20\u306e\u4e0a\u6607\u3092\u8a8d\u3081\u305f\u30ea\u30a6\u30de\u30c1\u6027\u591a\u767a\u7b4b\u75db\u75c7\uff08PMR\uff09\u306e\u4e00\u4f8b. \u7b2c21\u56de\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. 2001.<\/li>\n
          22. \u68ee\u7950\u4e00\u6717, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u6df7\u5408\u6027\u7d50\u5408\u7d44\u7e54\u75c5\uff08\uff2d\uff23\uff34\uff24\uff09\u306b\u304a\u3051\u308b\u80ba\u75c5\u5909\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c41\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u7dcf\u4f1a. 2001.<\/li>\n
          23. \u9ad8\u57ce\u4e00\u90ce, \u7530\u4e2d\u5f26\u4e00, \u7532\u6590\u6cf0\u6587, \u4f50\u3005\u6728\u9686, \u9577\u53cb\u5b89\u5f18, \u9ed2\u6728\u660c\u5e78, \u4f0a\u8cc0\u7766\u4e86, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1.\u7d4c\u904e\u4e2d\u306b\u8d64\u82bd\u7403\u7646\u3092\u5408\u4f75\u3057\u305f\u5168\u8eab\u6027\u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\u306e\u4e00\u4f8b. \u7b2c45\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2001.<\/li>\n
          24. \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u4f50\u3005\u6728\u9686, \u9577\u53cb\u5b89\u5f18, \u9ed2\u6728\u660c\u5e78, \u4f0a\u8cc0\u7766\u4e86, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u5168\u8eab\u6027\u30a8\u30ea\u30c6\u30de\u30c8\uff0d\u30c7\u30b9\uff08SLE)\u306b\u304a\u3051\u308b\u80ba\u75c5\u5909\u306e\u691c\u8a0e. \u7b2c45\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a. 2001.<\/li>\n
          25. \u5ca1\u5c71\u662d\u5f66, \u9ed2\u6728\u660c\u5e78, \u77f3\u5d0e\u6df3\u4e09, \u677e\u5ca1\u96c5\u96c4, \u5c71\u53e3\u4e00\u6210, \u6a58\u5ba3\u7965, \u576a\u5185\u535a\u4ec1. ATL\u767a\u75c7\u5371\u967a\u56e0\u5b50\u3068\u3057\u3066\u306eHTLV\u30d7\u30ed\u30a6\u30a4\u30eb\u30b9\u91cf\u3068\u611f\u67d3\u7d30\u80de\u30af\u30ed\uff0d\u30ca\u30ea\u30c6\u30a3. \u7b2c60\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a. 2001.<\/li>\n
          26. Gao G, Stuver SO, Okayama A, Tsubouchi H, Mueller NE, Tabor E, Kurogi J. The minimal number of clones necessary to sequence in order to obtain the maximum information about hepatitis C virus quasipieces. A comparison of cases with and without liver cancer. 53rd annual meeting of the American Association for the study of liver diseases. 2002.<\/li>\n
          27. \u7530\u4e2d\u5f26\u4e00, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u9ed2\u6728\u660c\u5e78, \u9577\u53cb\u5b89\u5f18, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u80f8\u817a\u816b\u6458\u51fa\u5f8c\u306b\u591a\u5f69\u306a\u65e5\u548c\u898b\u611f\u67d3\u3092\u5448\u3057\u305fGood\u75c7\u5019\u7fa4\u306e\u4e00\u4f8b. \u7b2c71\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u897f\u65e5\u672c\u5730\u65b9\u4f1a\u7dcf\u4f1a. 2001.<\/li>\n
          28. \u5c0f\u7267\u4e98, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1, \u5bae\u570b\u5747, \u6625\u7530\u539a, \u934b\u5cf6\u4e00\u6a39. \u4e21\u4e0a\u773c\u77bc\u306epanniculitis\u3092\u4f34\u3063\u305fMikulicz\u75c5\u3068\u601d\u308f\u308c\u308b\uff11\u4f8b. \u7b2c23\u56de\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. 2002.<\/li>\n
          29. \u7532\u6590\u6cf0\u6587, \u4f50\u3005\u6728\u9686, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u7279\u767a\u6027\u8840\u5c0f\u677f\u6e1b\u5c11\u6027\u7d2b\u6591\u75c5\u3068\u81ea\u5df1\u514d\u75ab\u6027\u809d\u708e\u3092\u5408\u4f75\u3057\u305f\u6df7\u5408\u6027\u7d50\u5408\u7d44\u7e54\u75c5. \u7b2c46\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          30. \u9ed2\u6728\u660c\u5e78, \u5ca1\u5c71\u662d\u5f66, \u5ca1\u672c\u5c06\u5e78, \u9577\u53cb\u5b89\u5f18, \u4e2d\u6751\u8aa0\u53f8, \u7be0\u539f\u6b63\u5fb3, \u829d\u826f\u7950, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u576a\u5185\u535a\u4ec1. Sjogren\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u30de\u30a4\u30af\u30ed\u30ad\u30e1\u30ea\u30ba\u30e0\u306e\u691c\u8a0e. \u7b2c46\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          31. \u9db4\u6751\u4f73\u4eba\u5b50, \u7530\u4e2d\u5f26\u4e00, \u7532\u6590\u6cf0\u6587, \u9ed2\u6728\u660c\u5e78, \u4f50\u3005\u6728\u9686, \u9ce5\u539f\u5eb7\u6cbb, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u3092\u5408\u4f75\u3057\u305fMPO-ANCA\u967d\u6027\u80a5\u539a\u6027\u786c\u819c\u708e\u306e\u4e00\u4f8b. \u7b2c46\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          32. \u85e4\u5143\u5343\u7d75, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78, \u9577\u53cb\u5b89\u5f18, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u5287\u75c7\u809d\u708e\u7d4c\u904e\u4e2d\u306b\u5408\u4f75\u3057\u305f\u80ba\u30a2\u30b9\u30da\u30eb\u30ae\u30eb\u30b9\u75c7\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c42\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          33. \u7532\u6590\u6cf0\u6587, \u6751\u4e95\u5e78\u4e00, \u4f50\u3005\u6728\u9686, \u7530\u4e2d\u5f26\u4e00, \u9ed2\u6728\u660c\u5e78, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1, \u5c4b\u4eae. \u8457\u660e\u306a\u7e26\u9694\u304a\u3088\u3073\u5f8c\u8179\u819c\u6c17\u816b\u3092\u4f34\u3063\u305fBacteroides thetaiotaomicron\u611f\u67d3\u75c7\u306e\u4e00\u4f8b. \u7b2c76\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          34. \u7530\u4e2d\u5f26\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \uff28\uff34\uff2c\uff36-1\u611f\u67d3\u306b\u304a\u3051\u308bclonal evolution. \u7b2c61\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          35. \u68ee\u7950\u4e00\u6717, \u9ed2\u6728\u660c\u5e78, \u6cb3\u91ce\u5c1a\u5b50, \u7532\u6590\u6cf0\u6587, \u7530\u4e2d\u5f26\u4e00, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u809d\u81bf\u760d\u3001\u80ba\u81bf\u760d\u306b\u5de6\u5168\u773c\u7403\u708e\u3092\u5408\u4f75\u3057\u305fKlebsiella pneumoniae\u611f\u67d3\u75c7\u306e\uff11\u4f8b. \u7b2c72\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u897f\u65e5\u672c\u5730\u65b9\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          36. \u5c71\u5143\u7f8e\u4fdd\u5b50, \u677e\u5c71\u5f18\u7d00, \u4f50\u3005\u6728\u9686, \u7532\u6590\u6cf0\u6587, \u9ed2\u6728\u660c\u5e78, \u5c71\u7530\u7422\u4e5f, \u7530\u4e2d\u5f26\u4e00, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1, \u5929\u91ce\u6b63\u5b8f, \u4e38\u585a\u6d69\u52a9. Rothmann-Makai\u75c7\u5019\u7fa4\u306e\u4e00\u4f8b. \u7b2c24\u56de\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a. 2002.<\/li>\n
          37. \u5ca1\u5c71\u662d\u5f66. HTLV-\uff11\u611f\u67d3\u306e\u30a2\u30a6\u30c8\u30ab\u30e0. \u7b2c72\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u897f\u65e5\u672c\u5730\u65b9\u4f1a\u7dcf\u4f1a. 2002.<\/li>\n
          38. Okayama A, Tanaka G, Stuver SO, Hsieh C, Tachibana N, Mueller NE, Tsubouchi H. The clonal expansion of HTLV-1 infected cells: A comparison between seroconverters and long-term carriers. The 11th International conference on human retrovirology : HTLV and related viruses. 2003.<\/li>\n
          39. Hisada M, Stuver SO, Li H, Sawada T, Okayama A, Mueller NE. Age-and sex-matched comparison of viral markers among HTLV-I carriers in Japan and Jamaica. The 11th International conference on human retrovirology : HTLV and related viruses. 2003.<\/li>\n
          40. Birmann B, Mueller NE, Okayama A, Tachibana N, Tsubouchi H, Hsieh C, Harn D, Stuver SO. Serologic evidence for type 1 dysregulation in healthy adults with humann T-lymphotropic virus type 1. The 11thInternational conference on humann retrovirology : HTLV and related viruses. 2003.<\/li>\n
          41. \u7530\u4e2d\u5f26\u4e00, \u5ca1\u5c71\u662d\u5f66, \u7532\u6590\u6cf0\u6587, \u68ee\u7950\u4e00\u6717, \u5c71\u7530\u7422\u4e5f, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u576a\u5185\u535a\u4ec1. HTLV-1\u611f\u67d3\u7d30\u80de\u30af\u30ed\u30fc\u30f3\u306e\u7d4c\u6642\u7684\u5909\u5316. \u7b2c77\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          42. \u4f50\u3005\u6728\u79c0\u6cd5, \u65e5\u9ad8\u667a\u5fb3, \u4e45\u51a8\u6728\u5eb8\u5b50, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1, \u68ee\u4e0b\u548c\u5e83, \u6d5c\u7530\u5065\u55e3, \u5ca1\u90e8\u5c1a\u53f2, \u6df1\u898b\u6b66\u53f2, \u6751\u4e0a\u559c\u5247. \u6025\u6027\u578bATL\u60a3\u8005\u7d30\u80de\u306b\u304a\u3051\u308bTSLC\uff11\u907a\u4f1d\u5b50\u306e\u9ad8\u767a\u73fe. \u7b2c62\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          43. \u4f50\u3005\u6728\u79c0\u6cd5, \u65e5\u9ad8\u667a\u5fb3, \u4e45\u51a8\u6728\u5eb8\u5b50, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1, \u68ee\u4e0b\u548c\u5e83, \u6d5c\u7530\u5065\u55e3, \u5ca1\u90e8\u5c1a\u6587, \u6df1\u898b\u6b66\u53f2, \u6751\u4e0a\u559c\u5247.\u3000\u6025\u6027\u578bATL\u60a3\u8005\u7d30\u80de\u306b\u304a\u3051\u308bTSLC1\u907a\u4f1d\u5b50\u306e\u9ad8\u767a\u73fe. \u7b2c65\u56de\u65e5\u672c\u8840\u6db2\u5b66\u4f1a\u7dcf\u4f1a\u3001\u7b2c45\u56de\u65e5\u672c\u81e8\u5e8a\u8840\u6db2\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          44. \u7532\u6590\u6cf0\u6587, \u5409\u6fa4\u5927, \u5c71\u7530\u7422\u4e5f, \u68ee\u7950\u4e00\u6717, \u7530\u4e2d\u5f26\u4e00, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. Leukocytoclastic vasculitits\u306e\u7d44\u7e54\u50cf\u3092\u5448\u3057\u305f\u30a2\u30ec\u30eb\u30ae\u30fc\u6027\u8089\u82bd\u816b\u6027\u8840\u7ba1\u708e\u306e\u4e00\u4f8b. \u7b2c47\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          45. \u767d\u571f\u660e\u7f8e, \u7532\u6590\u6cf0\u6587, \u5c71\u7530\u7422\u4e5f, \u68ee\u7950\u4e00\u6717, \u4f50\u3005\u6728\u9686, \u7530\u4e2d\u5f26\u4e00, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u9ac4\u819c\u8133\u708e\u3092\u5448\u3057\u305f\u518d\u767a\u6027\u591a\u767a\u8edf\u9aa8\u708e\u306e\u4e00\u4f8b. \u7b2c47\u56de\u65e5\u672c\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          46. \u8c37\u53e3\u88d5\u5b50, \u5ca1\u5c71\u662d\u5f66, \u91ce\u5742\u751f\u90f7, \u5b89\u6c38\u7d14\u4e00\u6717, \u677e\u5ca1\u96c5\u96c4. HTLV-1\u30d7\u30ed\u30a6\u30a4\u30eb\u30b9\u306b\u304a\u3051\u308bDNA\u30e1\u30c1\u30eb\u5316\u306e\u9032\u5c55. \u7b2c62\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          47. \u68ee\u4e0b\u548c\u5e83, \u4f50\u3005\u6728\u79c0\u6cd5, \u65e5\u9ad8\u667a\u5fb3, \u4e45\u51a8\u6728\u5eb8\u5b50, \u5ca1\u5c71\u662d\u5f66, \u6d5c\u7530\u5065\u55e3, \u5ca1\u90e8\u5c1a\u6587, \u6751\u4e0a\u559c\u5247. \u30de\u30a4\u30af\u30ed\u30a2\u30ec-\u89e3\u6790\u306b\u3088\u308bATL\u7d30\u80de\u907a\u4f1d\u5b50\u767a\u73fe. \u7b2c62\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          48. \u5ca1\u5c71\u662d\u5f66. HTLV-1\u3068ATL\u767a\u75c7. \u7b2c26\u56de\u65e5\u672c\u533b\u5b66\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          49. \u5ca1\u5c71\u662d\u5f66. \u6e29\u6cc9\u4e8b\u6545\u306b\u3088\u308b\u30ec\u30b8\u30aa\u30cd\u30e9\u80ba\u708e\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u5bae\u5d0e\u770c\u5185\u79d1\u533b\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          50. \u5ca1\u5c71\u662d\u5f66. HTLV-1\u6297\u4f53\u967d\u8ee2\u8005\u306e\u30a6\u30a4\u30eb\u30b9\u30de\u30fc\u30ab\u30fc\u306e\u7d99\u6642\u7684\u5909\u5316. \u7b2c73\u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u897f\u65e5\u672c\u5730\u65b9\u4f1a\u7dcf\u4f1a. 2003.<\/li>\n
          51. \u9ad8\u57ce\u4e00\u90ce, \u767d\u571f\u660e\u7f8e, \u68ee\u7950\u4e00\u6717, \u7530\u4e2d\u5f26\u4e00, \u4f50\u3005\u6728\u9686, \u6751\u4e95\u5e78\u4e00, \u5ca1\u5c71\u662d\u5f66, \u576a\u5185\u535a\u4ec1. \u518d\u767a\u6027\u591a\u767a\u8edf\u9aa8\u708e\u5408\u4f75\u9ac4\u819c\u8133\u708e\u306b\u30b9\u30c6\u30ed\u30a4\u30c9\u304c\u6709\u52b9\u3067\u3042\u3063\u305f\uff11\u4f8b. \u7b2c27\u56de\u4e5d\u5dde\u6c96\u7e04\u652f\u90e8\u5b66\u8853\u96c6\u4f1a\uff08\u4e5d\u5dde\u30ea\u30a6\u30de\u30c1\u5b66\u4f1a\uff09. 2004.<\/li>\n<\/ol>\n

            \u3010\u305d\u306e\u4ed6\u3011<\/h4>\n
              \n
            1. \u5ca1\u5c71\u662d\u5f66. HTLV-1\u30ad\u30e3\u30ea\u30a2\u306e\uff73\uff68\uff99\uff7d\u91cf\u306e\u5206\u6790. \u5e73\u621012\u5e74\u5ea6\u6587\u90e8\u7701\u79d1\u7814\u7279\u5b9a\u7814\u7a76\uff08C\uff09 \u300cHTLV-1\u611f\u67d3\u3068\u95a2\u9023\u75be\u60a3\u306e\u30b3\u30db\u30fc\u30c8\u7814\u7a76\u300d\u7b2c2\u56de\u73ed\u4f1a\u8b70. 2001.<\/li>\n
            2. \u77f3\u5d0e\u6df3\u4e09, \u5ca1\u5c71\u662d\u5f66, \u9ed2\u6728\u660c\u5e78, \u576a\u5185\u535a\u4ec1. IL-PCR\u3092\u7528\u3044\u305f\u65b0\u3057\u3044HTLV-1\u691c\u51fa\u65b9\u6cd5\u306e\u958b\u767a. \u7b2c9\u56de\u5730\u57df\u304b\u3089\u767a\u4fe1\u3059\u308b\u79d1\u5b66\u6280\u8853\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0. 2003.<\/li>\n
            3. \u5ca1\u5c71\u662d\u5f66, \u7530\u4e2d\u5f26\u4e00. \u6bcd\u5150\u611f\u67d3\u5150\u306eHTLV-1\u611f\u67d3\u7d30\u80de\u30af\u30ed\uff0d\u30ca\u30ea\u30c6\u30a3\u306e\u7d99\u6642\u7684\u5909\u5316. \u7b2c2\u56de\u5e73\u621015\u5e74\u5ea6\u6587\u79d1\u7701\u79d1\u7814\u73ed\u4f1a\u8b70. 2004.<\/li>\n<\/ol>\n

              –<\/p>\n

              \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

              C. \u305d\u306e\u4ed6<\/h3>\n

              –<\/p>\n

              \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

              D. \u7279\u8a31\u51fa\u9858<\/h3>\n

              –<\/p>\n

              \"\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078\"<\/a><\/div>\n

              \u5185\u8a33\u6570<\/h2>\n

              A.\u8ad6\u6587\uff1a\u8457\u66f8(8)\u3001\u539f\u8457\uff0872\uff09\u3001\u75c7\u4f8b\u5831\u544a\uff08\u8ad6\u6587\uff09\uff0819\uff09\u3001\u7dcf\u8aac\uff089\uff09\u3000B.\u767a\u8868\uff1a\u5b66\u4f1a\u767a\u8868\uff0851\uff09\u3001\u305d\u306e\u4ed6\uff083\uff09 C.\u305d\u306e\u4ed6\uff080\uff09\u3000D.\u7279\u8a31\u51fa\u9858\uff080\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"

              A. \u8ad6\u6587 \u3010\u8457\u66f8\u3011 Mueller NE, Tachibana N, Stuver SO, Okayama A, Ishizaki J, Shishime E, Murai K, Shigemasa S, Tsuda […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false},"categories":[9],"tags":[],"_links":{"self":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/posts\/244"}],"collection":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/comments?post=244"}],"version-history":[{"count":0,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/posts\/244\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/media?parent=244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/categories?post=244"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/menekikansen\/wp-json\/wp\/v2\/tags?post=244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}